ArticleJournal of biopharmaceutical statistics2014
Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.
Article in Journal of biopharmaceutical statistics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.Journal of comparative effectiveness research · 2025Pooled it
- Financial burden of postoperative complications following colonic resection: A systematic review.Medicine · 2021Pooled it
- Trial
- Protocol for the health economic evaluation of nature-based social prescribing against loneliness alongside the RECETAS trials.BMC public health · 2026Article
- Ninety-Day Cost, Mortality and Hospital Disparities in Ischemic Stroke: Real-World Evidence from a Czech Administrative Database.Healthcare (Basel, Switzerland) · 2026Article
- Implementation costs and relationships between costs and outcomes in the Faith, Activity, and Nutrition program: a church-based intervention.Implementation science communications · 2026Article
- Markov-model cost-effectiveness evaluation of a cessation programme when tobacco policies are comprehensive.BMJ open · 2026Article
- Article
- Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis.Frontiers in oncology · 2026Article
- The Evolution of Value-Based Care: Why Cost-Effectiveness Matters in Gastroenterology.ACG case reports journal · 2025Article
- Survival Outcomes of Crowns with and without Repaired Endodontic Access Cavities: A Retrospective Propensity Score Matching Study.European endodontic journal · 2025Article
- Application of distributional cost-effectiveness analysis methodology in real-world studies: a scoping review protocol.BMJ open · 2025Article
- The clinical utility and cost-effectiveness of routine vitamin BThe South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025Article
- Cost-Effectiveness Analysis to Inform Randomized Controlled Trial Design in Chronic Pain Research: Methods for Guiding Decisions on the Addition of a Run-In Period.Principles and practice of clinical research (2015) · 2022Article
- Implementation costs of a community health worker delivered weight loss intervention in black churches serving underserved communities.Preventive medicine reports · 2020Article
- Economic burden and mental health of primary caregivers of perinatally HIV infected adolescents from Kilifi, Kenya.BMC public health · 2020Article
- The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.Health economics review · 2019Article
- Exploring the potential cost-effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high-income welfare society.BMC psychiatry · 2019Article
- Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.Journal of managed care & specialty pharmacy · 2018Article
- Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.Drugs & aging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cost-effectiveness analysis (CEA) is a method for evaluating the outcomes and costs of competing strategies designed to improve health, and has been applied to a variety of different scientific fields. Yet there are inherent complexities in cost estimation and CEA from statistical perspectives (e.g., skewness, bidimensionality, and censoring). The incremental cost-effectiveness ratio that represents the additional cost per unit of outcome gained by a new strategy has served as the most widely accepted methodology in the CEA. In this article, we call for expanded perspectives and reporting standards reflecting a more comprehensive analysis that can elucidate different aspects of available data. Specifically, we propose that mean- and median-based incremental cost-effectiveness ratios and average cost-effectiveness ratios be reported together, along with relevant summary and inferential statistics, as complementary measures for informed decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.